Sierra Oncology

Sierra Oncology is a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer. The company harnesses its deep scientific expertise to identify compounds that target the root cause of disease. Sierra Oncology's team takes an evidence-based approach to understand the limitations of current treatments and explore new ways to change the cancer treatment paradigm. Sierra Oncology is transforming promise into patient impact.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SAN MATEO, Calif.--(BUSINESS WIRE)--Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a mission to deliver transformative therapies for rare cancers, today announced the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for momelotinib, an ACVR1 / ALK2, JAK1 and JAK2 inhibitor in development for the treatment of myelofibrosis. “Today is truly momentous for everyone at Sierra Oncology and the patients we serve. This team

Sierra Oncology Announces Submission of New Drug Application for Momelotinib to US Food & Drug Administration

SAN MATEO, Calif.--(BUSINESS WIRE)---- $SRRA #ASCO22--Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a mission to deliver transformative therapies for rare cancers, today announced two abstracts have been accepted into the program for the Annual Meeting of the American Society of Clinical Oncology (ASCO) being held June 3-7, 2022, in Chicago and online. An abstract presenting the full data from the pivotal phase 3 MOMENTUM study in myelofibrosis patients who are symptomatic and a

Momelotinib Pivotal Phase 3 Data Receives Oral Presentation at American Society of Clinical Oncology Annual Meeting

SAN MATEO, Calif.--(BUSINESS WIRE)--Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a mission to deliver transformative therapies for rare cancers, today announced two abstracts have been accepted into the program for the 2022 Annual Meeting of the European Hematology Association (EHA). An abstract presenting the full data from the pivotal phase 3 MOMENTUM study in myelofibrosis patients who are symptomatic and anemic has been selected for oral presentation. Addi

Sierra Oncology Announces Oral Presentation of Momelotinib Pivotal Phase 3 Data at European Hematology Association Annual Meeting

SAN MATEO, Calif--(BUSINESS WIRE)--Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company with a mission to deliver targeted therapies that treat rare forms of cancer, today reported its financial and operating results for the first quarter ended March 31, 2022. “By entering into a merger agreement with GSK, we are one step closer to realizing our mission of delivering transformative therapies for patients with rare cancers, while also delivering compelling and certain val

Sierra Oncology Reports First Quarter 2022 Results

SAN MATEO, Calif.--(BUSINESS WIRE)--Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, granted stock options to twelve new employees as approved by the Compensation Committee of the Company's Board of Directors, under Sierra Oncology's 2018 Equity Inducement Plan. The 2018 Equity Inducement Plan is used exclusively for the grant of equity awards to individuals as an inducement material to such individuals ent

Sierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlaxoSmithKline

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Sierra Oncology, Inc (NasdaqGM: SRRA) to GlaxoSmithKline plc (NYSE: GSK). Under the terms of the proposed transaction, shareholders of Sierra will receive only $55.00 in cash for each share of Sierra that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequa

SIERRA ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sierra Oncology, Inc - SRRA

CEDARHURST, N.Y.--(BUSINESS WIRE)--Kuznicki Law PLLC is investigating the proposed sale of Sierra Oncology, Inc (NasdaqGM: SRRA) to GlaxoSmithKline plc (NYSE: GSK). Under the terms of the proposed transaction, shareholders of Sierra will receive only $55.00 in cash for each share of Sierra that they own. If you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, contact us toll free at 833-938-0905, via email (dk@kclasslaw.com), or vi

SIERRA ONCOLOGY INVESTOR ALERT - Kuznicki Law PLLC Investigates Proposed Sale of Sierra Oncology, Inc - SRRA

SAN DIEGO--(BUSINESS WIRE)--RayzeBio, Inc., a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, appointed Angie You, Ph.D., to its board of directors. Dr. You is a seasoned biotechnology executive and was recently the chief executive officer of Amunix Pharmaceuticals, Inc., where she orchestrated the sale of the Company to Sanofi for over $1.2 billion. She also serves on the board of ORIC Pharmaceuticals, Inc. “RayzeBio is at the foref

RayzeBio Appoints Angie You, Ph.D., to its Board of Directors

Wilmington, Delaware--(Newsfile Corp. - April 18, 2022) - Rigrodsky Law, P.A. is investigating Sierra Oncology, Inc. ("Sierra") (NASDAQ: SRRA) regarding possible breaches of fiduciary duties and other violations of law related to Sierra's agreement to be acquired by GlaxoSmithKline plc. Under the terms of the agreement, Sierra's shareholders will receive $55.00 in cash for each share of Sierra common stock they own.To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-sierra-oncology-inc.To contact Seth D....

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Sierra Oncology, Inc. Buyout

AbbVie

Crinetics Pharmaceuticals Inc

Halozyme Therapeutics

Turning Point Therapeutics

Check out these biotech stocks with exciting developments today.

Best Biotech Stocks To Buy Now? 5 To Know

Antares Pharma

Origin Bancorp Inc

NEW YORK , April 13, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Sierra Oncology , Inc. (NASDAQ: SRRA)'s sale to GlaxoSmithKline plc for $55.00 per share in cash. If you are a Sierra Oncology shareholder, click here to learn more about your rights and options.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates SRRA, ATRS, OBNK

NEW YORK , April 13, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Sierra Oncology, Inc. ("Sierra" or the "Company") (NASDAQ: SRRA), in connection with the proposed acquisition of the Company by GlaxoSmithKline plc (NYSE: GSK).  Under the terms of the merger agreement, the Company's shareholders will receive $55.00 in cash for each share of Sierra common stock owned.

SHAREHOLDER ALERT: Weiss Law Investigates Sierra Oncology, Inc.

Sierra Oncology (NASDAQ: SRRA) shares traded significantly higher after announcing the acquisition by GlaxoSmithKline PLC (LON: GSK) for $55 a share in cash. That represents a total equity value of $1.9 billion, attributed mainly to SRRA's Momelotinib, a differentiated mode of action with inhibitory activity and critical signalling pathways.

Late-Stage Biopharmaceutical Sierra Oncology announces acquisition by GSK

Late-phase cancer treatment company Sierra Oncology is up big today after being acquired by GlaxoSmithKline. SRRA stock is soaring.

Why Is Sierra Oncology (SRRA) Stock Up Today?

Sierra Oncology Inc (NASDAQ: SRRA) shares are trading significantly higher Wednesday after the company announced it will be acquired by GlaxoSmithKline PLC (NYSE: GSK) for $55 per share in cash, representing an approximate total equity value of $1.9 billion.  GSK believes Sierra.

Sierra Oncology Stock Is Soaring: Here's Why

Sierra Oncology Inc (NASDAQ:SRRA) stock is soaring today, up 38% at $54.52, after news that GlaxoSmithKline (GSK) is purchasing the company for $1.9 billion.

Sierra Oncology Stock Soars After Buyout

Shares of Sierra Oncology Inc. SRRA, +3.10% soared 37.3% in premarket trading on Wednesday after GlaxoSmithKline GSK, +0.11% GSK, +0.63% said it would buy the company for $1.9 billion. Sierra is developing treatments for rare types of cancer, including myelofibrosis, and announced in January that momelotinib met the primary and secondary endpoints in a Phase 3 clinical trial evaluating the experimental therapy as a treatment for myelofibrosis.

GlaxoSmithKline to buy Sierra Oncology for $1.9 billion

The deal comes ahead of GlaxoSmithKline's planned spinoff of its consumer health division in July.

Sierra Oncology Soars After Takeover by Glaxo

GlaxoSmithKline is adding another cancer asset to its portfolio by acquiring U.S.-based Sierra Oncology.

Why Sierra Oncology Stock Is Soaring Today

GlaxoSmithKline plc (NYSE: GSK) has agreed to acquire Sierra Oncology Inc (NASDAQ: SRRA) for $55 per share in cash, representing an approximate total equity value of $1.9 billion (£1.5 billion). Sierra's momelotinib complements GSK's Blenrep (belantamab.

GlaxoSmithKline Scoops Up Rare Cancer-Focused Sierra Oncology In $1.9B Cash Deal

GlaxoSmithKline plc (NYSE: GSK) announced it is buying Sierra Oncology, Inc (Nasdaq: SRRA) for $1.9 billion (£1.5 billion). These are the details.

Why GlaxoSmithKline (GSK) Is Buying Sierra Oncology (SRRA) For $1.9 Billion

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, an investor rights law firm, is investigating whether the sale of Sierra Oncology, Inc. (NASDAQ: SRRA) to GlaxoSmithKline plc for $55.00 per share in cash is fair to Sierra Oncology shareholders. Halper Sadeh encourages Sierra Oncology shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns

SRRA Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Sierra Oncology, Inc. Is Fair to Shareholders

Sierra Oncology Stock Soars After $1.9 Billion Takeover by GlaxoSmithKline

Pharmaceutical giant GlaxoSmithKline PLC said Wednesday that it is buying biopharmaceutical company Sierra Oncology Inc. for $1.9 billion, and backed its guidance.

GlaxoSmithKline to buy Sierra Oncology for $1.9 billion.

It is the fate of the small(er) drug developer – to be taken out just when all the hard yards have been put in. And it's exactly what's happened to Nasdaq-listed Sierra Oncology (NASDAQ:SRRA).

News for Sierra Oncology Stock (SRRA)